| abstract |
The present invention relates to tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, A compound of formula (I), or a tautomer thereof, for the treatment of a disease associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular accumulation of misfolded protein, selected from the group of ischemia; or to novel uses of pharmaceutically acceptable salts: |